Blue Jet Healthcare Limited (BJHL) has been assigned credit ratings by Care Ratings Limited. The company's Long Term / Short Term Bank Facilities of ₹275.00 crore have been rated CARE A+; Stable / CARE A1+. The rating rationale highlights BJHL's established track record, experienced promoters, and presence in niche product segments like contrast media intermediates, pharmaceutical intermediates (including CDMO offerings), and high-intensity sweeteners. The company's diversified product portfolio and long-standing relationships with global customers support stable order inflows. BJHL exhibits a strong profitability profile, with PBILDT margins ranging from 31% to 38% over the past three years, improving to 37.78% in FY25. The company also reported a strong ROCE of 40.35% in FY25. Its financial risk profile is characterized by negligible external debt and strong debt coverage indicators. However, the ratings are constrained by high customer and product concentration, a working capital-intensive business model, exposure to regulatory compliance, export-driven volatility, and execution risks associated with ongoing capacity expansion plans. The company plans a capex of approximately ₹1,300 crore over the next 3-4 years. The stable outlook reflects CareEdge Rating’s expectation that BJHL will maintain its market position and comfortable financial risk profile.